3 Companies Redefining Healthcare Innovation
This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in…
Does FDA’s Rolling Review Of COMP360 Psilocybin Depression Therapy Change The Bull Case For COMPASS Pathways (CMPS)?
In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin…
How Scientists Cracked the Ketamine Code for Depression
Summary: Ketamine has been a “miracle” for many with treatment-resistant depression, but its side effects and short duration…
AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. AtaiBeckley…
Can Deep Brain Stimulation Unlock Treatment-Resistant Depression?
Summary: For approximately 30% of people living with depression, standard medications and therapy simply do not work—a condition…
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003?
AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc…
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways to Announce New…
DNA test boosts recovery in treatment-resistant depression
A major new meta-analysis shows that a DNA test guiding antidepressant choice boosts recovery odds in treatment-resistant depression,…